Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate - PubMed (original) (raw)

. 2006 Apr 25;1(3):161-4.

doi: 10.1021/cb600086b.

Affiliations

• PMID: 17163663
• DOI: 10.1021/cb600086b

Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate

Xinyu Liu et al. ACS Chem Biol. 2006.

Abstract

Novel virosomal formulations of a synthetic oligosaccharide were prepared and evaluated as vaccine candidates against leishmaniasis. A lipophosphoglycan-related synthetic tetrasaccharide antigen was conjugated to a phospholipid and to the influenza virus coat protein hemagglutinin. These glycan conjugates were embedded into the lipid membrane of reconstituted influenza virus virosomes. The virosomal formulations elicited both IgM and IgG anti-glycan antibodies in mice, indicating an antibody isotype class switch to IgG. The antisera cross-reacted in vitro with the corresponding natural carbohydrate antigens expressed by leishmania cells. These findings support the concept of using virosomes as universal antigen delivery platform for synthetic carbohydrate vaccines.

PubMed Disclaimer

Similar articles

• The virosome concept for influenza vaccines.
  Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. Huckriede A, et al. Vaccine. 2005 Jul 8;23 Suppl 1:S26-38. doi: 10.1016/j.vaccine.2005.04.026. Vaccine. 2005. PMID: 16026906 Review.
• Influenza vaccines: the virosome concept.
  Wilschut J. Wilschut J. Immunol Lett. 2009 Feb 21;122(2):118-21. doi: 10.1016/j.imlet.2008.11.006. Epub 2008 Dec 25. Immunol Lett. 2009. PMID: 19100779 Review.
• Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
  de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A. de Vries JJ, et al. Vaccine. 2009 Feb 5;27(6):947-55. doi: 10.1016/j.vaccine.2008.11.046. Epub 2008 Dec 4. Vaccine. 2009. PMID: 19059296
• Influenza virosomes: a flu jab for malaria?
  Cavanagh DR, Remarque EJ, Sauerwein RW, Hermsen CC, Luty AJ. Cavanagh DR, et al. Trends Parasitol. 2008 Sep;24(9):382-5. doi: 10.1016/j.pt.2008.06.002. Epub 2008 Aug 5. Trends Parasitol. 2008. PMID: 18684667
• Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
  Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS, Sauerwein RW, Matile H, Zurbriggen R, Mazier D, Robinson JA, Pluschke G. Okitsu SL, et al. Chem Biol. 2007 May;14(5):577-87. doi: 10.1016/j.chembiol.2007.04.008. Chem Biol. 2007. PMID: 17524988

Cited by

• A Ferrier glycosylation/_cis_-dihydroxylation strategy to synthesize Leishmania spp. lipophosphoglycan-associated βGal(1,4)Man disaccharide.
  Budhathoki D, Deore B, Finn MG, Sanhueza CA. Budhathoki D, et al. RSC Adv. 2022 Oct 4;12(43):28207-28216. doi: 10.1039/d2ra05158c. eCollection 2022 Sep 28. RSC Adv. 2022. PMID: 36320230 Free PMC article.
• Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.
  Seeberger PH. Seeberger PH. Chem Rev. 2021 Apr 14;121(7):3598-3626. doi: 10.1021/acs.chemrev.0c01210. Epub 2021 Apr 1. Chem Rev. 2021. PMID: 33794090 Free PMC article. Review.
• Design and synthesis of multivalent α-1,2-trimannose-linked bioerodible microparticles for applications in immune response studies of Leishmania major infection.
  Rintelmann CL, Grinnage-Pulley T, Ross K, Kabotso DEK, Toepp A, Cowell A, Petersen C, Narasimhan B, Pohl N. Rintelmann CL, et al. Beilstein J Org Chem. 2019 Mar 11;15:623-632. doi: 10.3762/bjoc.15.58. eCollection 2019. Beilstein J Org Chem. 2019. PMID: 30931004 Free PMC article.
• Parasite Carbohydrate Vaccines.
  Jaurigue JA, Seeberger PH. Jaurigue JA, et al. Front Cell Infect Microbiol. 2017 Jun 12;7:248. doi: 10.3389/fcimb.2017.00248. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28660174 Free PMC article. Review.
• Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites.
  Möginger U, Resemann A, Martin CE, Parameswarappa S, Govindan S, Wamhoff EC, Broecker F, Suckau D, Pereira CL, Anish C, Seeberger PH, Kolarich D. Möginger U, et al. Sci Rep. 2016 Feb 4;6:20488. doi: 10.1038/srep20488. Sci Rep. 2016. PMID: 26841683 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information